Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 64400141

Drug Profile

JNJ 64400141

Alternative Names: Ad26-RSV-preF; Ad26.RSV.preF; JNJ-64400141; RSV Jr prophylactic vaccine - Janssen; RSV Senior prophylactic vaccine - Janssen; VAC-18193; VAC-18194

Latest Information Update: 07 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 02 Oct 2019 Safety and Immunogenicity data from a phase IIa trial in Respiratory syncytial virus infections presented at the IDWeek 2019 (IDW-2019)
  • 02 Oct 2019 Efficacy and pharmacokinetics data from a phase IIa trial in Respiratory syncytial virus infections presented at the IDWeek 2019 (IDW-2019)
  • 03 Sep 2019 JNJ 64400141 receives Breakthrough Therapy status for Respiratory syncytial virus infections (In the elderly) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top